TIDMAMS
RNS Number : 6604W
Advanced Medical Solutions Grp PLC
18 April 2023
18 April 2023
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing technologies ,
announces that on 14 April 2023, the Board, following a
recommendation from its Remuneration Committee, granted new
nil-cost share options to the following Directors/PDMRs under the
existing Advanced Medical Solutions Long Term Incentive Plan (the
'LTIP'). The vesting of these options is based on achieving certain
performance criteria for the three years prior to vesting. The
performance criteria under the LTIP scheme is split equally between
Earnings Per Share (EPS) growth against fixed targets and Total
Shareholder Return (TSR) against a comparator group. The
performance criteria have remained unchanged for the last nine
years. Directors/PDMRs are required to hold the LTIPs for a period
of two years following vesting.
Director/PDMR Options prior Options granted Resultant LTIP
to grant holdings
Chris Meredith
Chief Executive
Officer 733,327 3 24,805 1,058,132
============== ================ ===============
Eddie Johnson
Chief Financial
Officer 317,696 134,063 451,759
============== ================ ===============
Advanced Medical Solutions Group plc also announces that on 14
April 2023, the Board, following a recommendation from its
Remuneration Committee, granted new share options to the following
Directors/PDMRs under the Advanced Medical Solutions Deferred
Annual Bonus Plan (the '2014 DAB').
This award is in respect of the part of their bonus that the
Directors/PDMRs are compulsorily required to defer for the 2022
financial year. These options vest at the end of three years.
Details of the current DAB holdings of the Directors following
these awards are shown below:
Director/PDMR Options prior Options granted Resultant holding
to grant/exercise
Chris Meredith
Chief Executive
Officer 6,219 31,138 37,357
=================== ================ ==================
Eddie Johnson
Chief Financial
Officer 12,737 13,528 26,265
=================== ================ ==================
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Chris Meredith
---------------------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status: Chief Executive Officer
---------------------------------------------------------------------
b) Initial notification/Amendment: Initial Notification
---------------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name: Advanced Medical Solutions Group plc
---------------------------------------------------------------------
b) LEI: 213800HJP6OWOSZI1L74
---------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the financial instrument, type of instrument:
Ordinary Shares of 5p
Identification code: GB0004536594
---------------------------------------------------------------------
b) Nature of the transactions:
1. Grant of options under the Advanced Medical Solutions
Long Term Incentive Plan
2. Grant of options under the Advanced Medical Solutions
Deferred Annual Bonus Plan
---------------------------------------------------------------------
c) Price(s) and volume(s):
Sale of shares: Price(s) Volume(s)
1. - 324,805
----------
2. - 31,138
----------
---------------------------------------------------------------------
d) Aggregated information:
Aggregated volume: n/a
Aggregated price: n/a
---------------------------------------------------------------------
e) Date of the transaction: 14/04/2023
---------------------------------------------------------------------
f) Place of the transaction: Outside of a trading venue
---------------------------------------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Eddie Johnson
---------------------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status: Chief Financial Officer
---------------------------------------------------------------------
b) Initial notification/Amendment: Initial Notification
---------------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name: Advanced Medical Solutions Group plc
---------------------------------------------------------------------
b) LEI: 213800HJP6OWOSZI1L74
---------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the financial instrument, type of instrument:
Ordinary Shares of 5p
Identification code: GB0004536594
---------------------------------------------------------------------
b) Nature of the transactions:
1. Grant of options under the Advanced Medical Solutions
Long Term Incentive Plan
2. Grant of options under the Advanced Medical Solutions
Deferred Annual Bonus Plan
---------------------------------------------------------------------
c) Price(s) and volume(s):
Sale of shares: Price(s) Volume(s)
1. - 134,063
----------
2. - 13,528
----------
---------------------------------------------------------------------
d) Aggregated information:
Aggregated volume: n/a
Aggregated price: n/a
---------------------------------------------------------------------
e) Date of the transaction: 14/04/2023
---------------------------------------------------------------------
f) Place of the transaction: Outside of a trading venue
---------------------------------------------------------------------
- End -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Matthew Neal / Lucy Featherstone AMS@consilium-comms.com
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Gary Clarence / David Anderson
HSBC Bank PLC (Broker) Tel: 44 (0) 20 7991
8888
Sam McLennan / Joe Weaving / Stephanie
Cornish
About Advanced Medical Solutions Group plc - see
www.admedsol.com
AMS is a world-leading independent developer and manufacturer of
innovative tissue-healing technology, focused on quality outcomes
for patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, internal
fixation devices and internal sealants, which it markets under its
brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) .
AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(R) brand as well as under
white label. Since 2019, the Group has made five acquisitions:
Sealantis, an Israeli developer of innovative internal sealants;
Biomatlante, a French developer and manufacturer of surgical
biomaterials, Raleigh, a leading UK coater and converter of
woundcare and bio-diagnostics materials, AFS Medical, an Austrian
specialist surgical business and Connexicon, an Irish tissue
adhesives specialist.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Ireland, Germany, France and Israel. Established in 1991,
the Group has more than 800 employees. For more information, please
see www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBRGDSGDBDGXI
(END) Dow Jones Newswires
April 18, 2023 13:22 ET (17:22 GMT)
Advanced Medical Solutions (AQSE:AMS.GB)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Medical Solutions (AQSE:AMS.GB)
Historical Stock Chart
From May 2023 to May 2024
